We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

and Taltz and Olumiant for immunology. After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its ...

Over the past six months, Eli Lilly (NYSE: LLY ... including immunosuppressant Taltz, cancer drug Verzenio, and fast-acting insulin Humalog. And that's before we get into the company's pipeline ...

Eli Lilly boasts a diverse portfolio of other key products across various therapeutic areas. The company's oncology and immunology portfolios, including drugs like Verzenio and Taltz, continue to ...

During the last three months, 7 analysts shared their evaluations of Eli Lilly LLY, revealing diverse ... and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

PHILADELPHIA (AP) Kino Lilly Jr. scored 34 points and made eight 3-pointers as Brown beat Pennsylvania 88-79 on Friday night. Lilly shot 9 for 16, including 8 for 9 from 3-point range, and 8 of 9 ...